At the ESMO Congress 2024, Andrea Necchi, MD, of San Raffaele Hospital and Scientific Institute, and Karine Tawagi, MD, of University of Illinois, highlight some the challenges that currently exist in the treatment of penile cancer, including “suboptimal” therapy options in the neoadjuvant and adjuvant space and a need for better biomarkers. Dr. Necchi also opines on the trials that have him excited about the future of treatment in this rare disease, such as HERCULES. ...
Testicular, Penile, and Rare Malignancies
Advertisement
Latest News
Paclitaxel, ifosfamide, and cisplatin is a combination commonly used for the treatment of germ cell tumors.
A recent dose-escalation study has demonstrated the safety and efficacy of cabo/nivo or cabo/nivo/ipi for several GU cancers.
Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.
A recent trial provides the first evidence of efficacy from ICIs in PSCC with a manageable safety profile.
The SWENOTECA cancer care program sought to evaluate survival, toxicity in patients treated with HDCT from 2011 through 2021.
A study to determine the potential utility of ADCs targeting TROP-2 in both localized PSCC and distant metastases.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
Dr. Choueiri outlines the importance of experts putting their heads together to decide on how to approach gray areas.
Advertisement
Advertisement
Latest News
In part two of this roundtable, multidisciplinary approaches to managing MIBC are discussed.
The first segment of this roundtable series focuses on the latest developments in MIBC treatment, including the NIAGARA trial
In the final part of this roundtable series, the panelists share their thoughts on the most anticipated upcoming trials.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.